<DOC>
	<DOCNO>NCT01153217</DOCNO>
	<brief_summary>Most study find consistent drug-specific association bone loss controversial data respect effect protease inhibitor ( PIs ) publish . The evident finding respect issue pronounce decrease bone mineral density ( BMD ) patient first week receive tenofovir ( TDF ) -containing regimen , probably effect TDF phosphorus balance vitamin D metabolism .</brief_summary>
	<brief_title>Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density</brief_title>
	<detailed_description>The prevalence osteoporosis HIV-infected patient could three time great compare HIV-uninfected subject , accord result meta-analytical review cross-sectional publish study . The analysis include data 884 HIV-infected patient 654 HIV-uninfected control . Sixty-seven percent HIV population reduce bone mineral density ( BMD ) , 15 % osteoporosis ( OR 6.4 3.7 , respectively , compare HIV-uninfected control ) . In meta-analysis , author evaluate role antiretroviral therapy ( ART ) BMD , compare 202 antiretroviral-naive 824 ART-treated patient , patient treatment 2.5-fold increase odds prevalent reduce BMD osteoporosis . And finally , 410 non-protease inhibitor ( PI ) -treated HIV patient compare 791 patient receive PI-containing regimen , PIs increase odds reduce BMD osteoporosis . As well , study support data impair BMD HIV-infected patient start antiretroviral therapy . These result let u confirm HIV antiretroviral therapy contribute decrease BMD . However , study find consistent drug-specific association bone loss controversial data respect effect PIs publish . The evident finding respect issue pronounce decrease BMD patient first week receive tenofovir ( TDF ) -containing regimen , probably effect TDF phosphorus balance vitamin D metabolism .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Adult patient ( =/+18 year old ) diagnosis HIV1 infection . 2 . Current HAART include tenofovir plus emtricitabine/lamivudine plus PI , NNRTI raltegravir start least 12 month . 3 . Tscore ≤2 measure DEXA ( within last 6 month ) . 4 . Maintained undetectable plasma HIV1 RNA ( VL &lt; 50 copies/mL ) least 12 month . 5 . Absence suspect documented resistance mutation RT associate abacavir . 6 . Voluntary write informed consent . 1 . History intolerance , toxicity virological failure abacavir . 2 . HLA B*5701 positive . 3 . Secondary osteoporosis/osteopenia ( vitamin D testosterone deficit , thyroid disease , … ) 4 . Therapy biphosphonates within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>HIV-infection</keyword>
	<keyword>BMD</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteopenia</keyword>
</DOC>